|
Ertapenem is a carbapenem antibiotic marketed by Merck as Invanz. It is structurally very similar to meropenem in that it possesses a 1-β-methyl group. Other members of the carbapenem group (imipenem, doripenem, and meropenem) are broadly active antibacterials that are used for infections caused by difficult to treat or multidrug-resistant bacteria (such as ESBL expressing Klebsiella pneumonia). They have very short serum half-lives and must be administered by intravenous infusion every 6 to 8 hours. Ertapenem differs from other carbapenems in having a somewhat less broad spectrum of activity (not against Pseudomonas aeruginosa ), and in that its extended serum half-life allows it to be administered once every 24 hours. ==Indications== Ertapenem has been designed to be effective against Gram-negative and Gram-positive bacteria. It is not active against MRSA, ampicillin-resistant enterococci, ''Pseudomonas aeruginosa'', or ''Acinetobacter'' species. Ertapenem also has clinically useful activity against anaerobic bacteria. Ertapenem has been shown to be active against most isolates of the following micro-organisms ''in vitro'' and in clinical infections. Aerobic and facultative gram-positive microorganisms: Staphylococcus aureus (methicillin-susceptible isolates only), Streptococcus agalactiae, Streptococcus pneumoniae (penicillin-susceptible isolates only), Streptococcus pyogenes, Note: Methicillin-resistant staphylococci and Enterococcus spp. are resistant to ertapenem. Aerobic and facultative gram-negative microorganisms: Escherichia coli, Haemophilus influenzae, Klebsiella pneumoniae, Moraxella catarrhalis, Proteus mirabilis, Anaerobic microorganisms: Bacteroides fragilis, Bacteroides distasonis, Bacteroides ovatus, Bacteroides thetaiotaomicron, Bacteroides uniformis, Clostridium clostridioforme, Eubacterium lentum, Peptostreptococcus species, Porphyromonas asaccharolytica, Prevotella bivia, Ertapenem is marketed by Merck as a first-line treatment for community-acquired infections. It should not be used as empirical treatment for hospital-acquired infections because of its lack of activity against ''Pseudomonas aeruginosa''. In practice, it is reserved primarily for use against Extended spectrum beta-lactamase (ESBL)-producing and high level AmpC-producing Gram-negative bacteria. 抄文引用元・出典: フリー百科事典『 ウィキペディア（Wikipedia）』 ■ウィキペディアで「ertapenem」の詳細全文を読む スポンサード リンク
|